Los fenómenos paranormales han fascinado a la humanidad desde tiempos inmemoriales. Historias de fantasmas, avistamientos de OVNIs, telequinesis y comunicación con el más allá han capturado nuestra imaginación colectiva y han alimentado innumerables debates. Pero & …
Durante décadas, los científicos han estado intrigados por una misteriosa porción de nuestro genoma conocida como “ADN basura”. Este término, acuñado en la década de 1960, sugiere que esta parte de nuestro ADN no tiene función y es simplemen …
ADN "basura": La verdad oculta detrás de un nombre engañoso Read More »
Biogen Inc. and Sage Therapeutics, Inc. announced the U.S. Food and Drug Administration approved ZURZUVAE™ 50 mg for adults with postpartum depression.
Ascentage Pharma announced that lisaftoclax, a novel Bcl-2 inhibitor and one of the company’s core assets, has been cleared by the US Food and Drug Administration to enter a global registrational Phase III study for treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were BTKi previously treated.
Akeso Inc. announced that eClinical Medicine, a sub-journal of The Lancet, recently published the results of a phase II clinical trial of ivonescimab combined with chemotherapy for the treatment of non-small cell lung cancer.
Recently, Venus Medtech Inc., a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced the Investigational Device Exemption full approval for its in-house developed VenusP-Valve from the U.S. Food and Drug Administration.
The market opportunity for pulmonary arterial hypertension drugs stretches well beyond the 500–1,000 Americans diagnosed with the disease each year—and biopharma is taking note.
Opportunity and New Therapies Are Driving Interest in a Rare Cardiovascular Disease Read More »
Bavarian Nordic A/S announced positive topline results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of its virus-like particle -based chikungunya virus vaccine candidate, CHIKV VLP in adults and adolescents aged 12 to 64 years of age.
Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, announced that it will host a live webcast on Monday, August 7, 2023 at 8:00 a.m. ET to provide a business update.
The U.S. Food and Drug Administration approved Zurzuvae, the first oral medication indicated to treat postpartum depression in adults.
FDA Approves First Oral Treatment for Postpartum Depression Read More »
